Does Mao Inhibitors Interact with Brigatinib?
Mao Inhibitors and Brigatinib have a moderate drug interaction according to U.S. FDA drug labeling data. Coadministration increases brigatinib plasma concentrations, which may increase the incidence of adverse reactions. Dose reduction recommended if coadministration unavoidable. The mechanism involves cyp3a inhibition increases brigatinib exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Brigatinib Class
- Kinase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Mao Inhibitors and Brigatinib occurs because cyp3a inhibition increases brigatinib exposure. Clinically, this means coadministration increases brigatinib plasma concentrations, which may increase the incidence of adverse reactions. dose reduction recommended if coadministration unavoidable. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Mao Inhibitors and your doctor is considering prescribing Brigatinib (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider